TAK 816

Drug Profile

TAK 816

Alternative Names: CRM-Hib vaccine conjugate - Novartis; Hib-CRM197 vaccine conjugate - Novartis; Monovalent Hib vaccine - Novartis; PRP-CRM197 conjugate Hib vaccine - Novartis; TAK-816; Vaxim Hib

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Chiron
  • Developer GlaxoSmithKline
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections

Most Recent Events

  • 22 Jan 2016 Registered for Haemophilus infections (In infants, Prevention) in Japan (IM)
  • 01 Mar 2015 Takeda completes a phase III trial for Haemophilus infections (in infants, prevention) in Japan (NCT02074345)
  • 01 Nov 2014 Novartis initiates enrolment in a phase III extension trial for Haemophilus infections (In children, In infants, Prevention) in China (NCT02139228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top